Gland Pharma Ltd

Gland Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gland Pharma Ltd

₹ 1,830 0.04%
14 Nov - close price
glandpharma.com BSE: 543245 NSE: GLAND
About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Key Points

Product Portfolio
The company is one of the largest and fastest-growing injectable-focused companies, providing 89+ product SKUs, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, across 15+ therapeutic areas. [1] [2]

The company launched 85 new molecules between FY22 and FY24, and introduced 12 new molecules, including Cetrorelix Acetate, Tranexamic Acid, Eribulin mesylate, Plerixafor, Nelarabine, etc., in the US market during H1 FY25. [3] [4]

Website BSE NSE
  • Market Cap ₹ 30,150 Cr.
  • Current Price ₹ 1,830
  • High / Low ₹ 2,131 / 1,200
  • Stock P/E 38.2
  • Book Value ₹ 580
  • Dividend Yield 0.98 %
  • ROCE 11.9 %
  • ROE 7.81 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.4%

Cons

  • Stock is trading at 3.15 times its book value
  • Company has a low return on equity of 9.22% over last 3 years.
  • Promoter holding has decreased over last 3 years: -6.03%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE MidCap Nifty Pharma

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
1,044 938 785 1,209 1,373 1,545 1,537 1,402 1,406 1,384 1,425 1,506 1,487
748 649 617 915 1,049 1,189 1,179 1,137 1,109 1,024 1,077 1,138 1,173
Operating Profit 297 290 168 294 324 356 359 264 297 360 348 368 314
OPM % 28% 31% 21% 24% 24% 23% 23% 19% 21% 26% 24% 24% 21%
66 62 -18 38 53 37 42 51 60 58 44 58 84
Interest 2 3 2 5 6 5 10 6 6 23 7 12 8
Depreciation 37 38 38 65 81 105 93 92 94 96 96 101 106
Profit before tax 324 311 111 261 290 283 298 218 257 299 288 313 284
Tax % 26% 25% 29% 26% 33% 32% 35% 34% 36% 32% 35% 31% 35%
241 232 79 194 194 192 192 144 164 205 187 215 184
EPS in Rs 14.65 14.08 4.78 11.79 11.78 11.65 11.68 8.73 9.93 12.42 11.32 13.08 11.15
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
2,633 3,463 4,401 3,625 5,665 5,616 5,801
1,678 2,161 2,890 2,600 4,332 4,348 4,412
Operating Profit 955 1,302 1,510 1,025 1,333 1,269 1,389
OPM % 36% 38% 34% 28% 24% 23% 24%
139 135 224 184 170 214 244
Interest 7 3 5 7 26 42 50
Depreciation 95 99 110 147 345 378 399
Profit before tax 993 1,335 1,619 1,055 1,133 1,063 1,184
Tax % 22% 25% 25% 26% 32% 34%
773 997 1,212 781 772 699 790
EPS in Rs 49.88 60.94 73.75 47.42 46.90 42.40 47.97
Dividend Payout % 0% 0% 0% 0% 43% 42%
Compounded Sales Growth
10 Years: %
5 Years: 16%
3 Years: 8%
TTM: -2%
Compounded Profit Growth
10 Years: %
5 Years: -2%
3 Years: -17%
TTM: 14%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 2%
1 Year: 3%
Return on Equity
10 Years: %
5 Years: 12%
3 Years: 9%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 16 16 16 16 16 16 16
Reserves 3,631 5,887 7,141 7,942 8,707 9,134 9,546
5 4 5 4 372 314 302
435 589 671 814 1,515 1,708 1,935
Total Liabilities 4,086 6,496 7,834 8,778 10,611 11,173 11,800
968 954 1,502 1,571 3,947 4,147 4,403
CWIP 188 338 191 177 238 151 209
Investments 0 0 155 0 0 0 0
2,929 5,204 5,986 7,030 6,426 6,875 7,188
Total Assets 4,086 6,496 7,834 8,778 10,611 11,173 11,800

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
701 605 791 364 997 915
-761 -1,520 -999 1,211 -1,749 1,718
-7 1,238 35 15 -799 -433
Net Cash Flow -67 323 -174 1,590 -1,552 2,199

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 83 71 89 88 100 99
Inventory Days 250 312 205 421 278 294
Days Payable 82 98 80 127 129 143
Cash Conversion Cycle 251 285 214 382 250 250
Working Capital Days 161 169 168 242 155 173
ROCE % 28% 25% 15% 14% 12%

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
57.86% 57.86% 57.86% 57.86% 57.86% 57.86% 51.83% 51.83% 51.83% 51.83% 51.83% 51.83%
4.67% 4.33% 2.80% 4.91% 4.05% 3.59% 6.88% 4.48% 5.04% 6.90% 7.39% 7.90%
23.13% 23.23% 23.38% 22.45% 24.17% 25.23% 32.83% 35.37% 34.80% 33.27% 32.86% 32.63%
14.35% 14.59% 15.97% 14.78% 13.93% 13.32% 8.46% 8.33% 8.33% 8.00% 7.93% 7.63%
No. of Shareholders 1,48,4691,50,5781,81,7471,61,6271,36,0211,22,3751,22,6651,22,3581,21,0751,13,7881,10,67197,151

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls